单侧与双侧助听器治疗年龄相关听力损失的随机临床试验
该单盲平行组随机临床试验纳入275例50岁及以上、既往助听器使用少于3个月的年龄相关听力损失患者,比较双侧与单侧助听器3个月时的获益。结果显示双侧组APHAB获益评分较单侧组高5.29%(95%CI -8.79%至-1.80%),但该差异的临床意义尚不明确。
要点
- 双侧助听器自报获益评分显著高于单侧,但临床意义待确认。
- 单侧与双侧助听器均可产生个体水平的有意义的改善。
- 结果尚不足以建立双侧验配的标准实践推荐。
核心结论
- 双侧助听器较单侧提供更大的自报获益,但未明确达到临床意义阈值。
- 两种配置均产生个体有意义的改善,尚不能确立双侧验配为标准推荐。
研究设计与样本
- 单盲平行组随机临床试验,在美国杜克大学健康系统和范德堡大学听力学诊所开展。
- 2021至2024年纳入275例50岁及以上、年龄相关听力损失、既往助听器使用少于3个月且寻求助听器的参与者。
- 随机分配至双侧或单侧助听器组,主要终点为3个月,分析基于意向性治疗。
主要发现
- 单侧组(n=136)APHAB获益评分均值(SD)为14.41(13.02),双侧组(n=139)为19.74(15.18)。
- 双侧组较单侧组APHAB获益评分平均差异为-5.29%(95%CI -8.79%至-1.80%)。
- 两组均显示APHAB获益评分改善。
关键数值与推荐
- 主要结局为APHAB整体评分从基线(未助听)至3个月(助听)的获益差值。
- 主要分析为3个月APHAB获益评分的线性回归,协变量包括临床中心和助听器分组。
- 获益定义为3个月主要终点(助听)APHAB整体评分与基线(治疗前/未助听)的差值。
临床怎么用
- 临床决策时可告知患者双侧助听器自报获益略优于单侧,但个体获益均存在。
- 鉴于临床意义不明确,验配方案应结合患者偏好与个体情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Age-related hearing loss (ARHL) is ubiquitous and is characterized as bilateral symmetrical sensorineural and mild to moderate in degree. When left untreated, significant impacts arise in domains including communication, psychosocial, cognitive and physical health. Data demonstrating the effectiveness of unilateral or bilateral hearing aids (HAs) as the standard treatment are lacking. OBJECTIVE: To determine whether bilateral HAs provide more benefit compared with a unilateral HA. DESIGN, SETTING, AND PARTICIPANTS: This single-blinded parallel-group randomized clinical trial was conducted at audiology clinics at Duke University Health System and Vanderbilt University from 2021 to 2024 with the primary outcome duration of 3 months. Participants were aged 50 years or older with ARHL with less than 3 months of prior HA use seeking HAs. Participants were randomly assigned to the bilateral or unilateral group. Analyses were based on intention to treat. INTERVENTIONS: Commercially available prescription receiver-in-the-canal HAs. MAIN OUTCOMES AND MEASURES: The hypothesis was that bilateral HAs would provide greater benefit than a unilateral HA. The primary outcome was HA benefit as measured using the Abbreviated Profile of Hearing Aid Benefit (APHAB) score. Benefit was defined as the difference in APHAB-global score at the 3-month primary end point (aided) from baseline (pretreatment/unaided) APHAB scores. The primary analysis was a linear regression of the APHAB benefit score at 3 months with clinical site and hearing aid assignment as covariates. RESULTS: A total of 275 participants were included (148 female [53.8%]; mean [SD] age, 70.9 [7.9] years). The mean (SD) APHAB benefit score was 14.41 (13.02) for the unilateral group (n = 136) and 19.74 (15.18) for the bilateral group (n = 139). These results indicate that both groups had benefit as demonstrated in APHAB benefit scores, with the bilateral group experiencing significantly higher benefit compared with the unilateral group with a mean difference in APHAB benefit score of -5.29% (95% CI, -8.79% to -1.80%) between the groups. CONCLUSIONS AND RELEVANCE: The trial results indicate that bilateral HAs yield greater self-reported benefit than unilateral HAs; however, while statistically detectable, it is not clear whether this reaches the threshold for clinical meaningfulness. Both configurations produced individually meaningful improvements. These results inform, but do not yet establish, a standard-of-practice recommendation for bilateral fitting. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04739436.
引用
- Smith SL, Ricketts TA, Kilpatrick KW, et al. Unilateral and Bilateral Hearing Aids for Age-Related Hearing Loss: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 42658545. doi:10.1001/jamaoto.2026.2401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。